Advertisement
Australia markets closed
  • ALL ORDS

    7,837.40
    -100.10 (-1.26%)
     
  • ASX 200

    7,575.90
    -107.10 (-1.39%)
     
  • AUD/USD

    0.6535
    +0.0012 (+0.18%)
     
  • OIL

    83.66
    +0.09 (+0.11%)
     
  • GOLD

    2,349.60
    +7.10 (+0.30%)
     
  • Bitcoin AUD

    98,008.77
    -1,190.09 (-1.20%)
     
  • CMC Crypto 200

    1,383.71
    -12.82 (-0.92%)
     
  • AUD/EUR

    0.6108
    +0.0035 (+0.57%)
     
  • AUD/NZD

    1.0994
    +0.0037 (+0.33%)
     
  • NZX 50

    11,805.09
    -141.34 (-1.18%)
     
  • NASDAQ

    17,718.30
    +287.79 (+1.65%)
     
  • FTSE

    8,139.83
    +60.97 (+0.75%)
     
  • Dow Jones

    38,239.66
    +153.86 (+0.40%)
     
  • DAX

    18,161.01
    +243.73 (+1.36%)
     
  • Hang Seng

    17,651.15
    +366.61 (+2.12%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

Gilead Earnings Miss, Revenue Beats In Q4

Gilead Earnings Miss, Revenue Beats In Q4
Gilead Earnings Miss, Revenue Beats In Q4

Investing.com - Gilead (NASDAQ:GILD) reported on Tuesday fourth quarter earnings that missed analysts' forecasts and revenue that topped expectations.

Gilead announced earnings per share of $1.3 on revenue of $5.88B. Analysts polled by Investing.com anticipated EPS of $1.67 on revenue of $5.71B. That with comparison to EPS of $1.44 on revenue of $5.8B in the same period a year before. Gilead had reported EPS of $1.75 on revenue of $5.6B in the previous quarter. Analysts are expecting EPS of $1.73 and revenue of $5.56B in the upcoming quarter.

Gilead shares are up 3.79% from the beginning of the year , still down 4.01% from its 52 week high of $70.26 set on February 4, 2019. They are under-performing the Nasdaq 100 which is up 6.04% year to date.

ADVERTISEMENT

Gilead shares lost 1.82% in after-hours trade after the report.

Gilead follows other major Healthcare sector earnings this month

Gilead's report follows an earnings beat by J&J on January 22, who reported EPS of $1.88 on revenue of $20.75B, compared to forecasts EPS of $1.87 on revenue of $20.8B.

Novartis ADR had beat expectations on January 29 with fourth quarter EPS of $1.32 on revenue of $12.4B, compared to forecast for EPS of $1.31 on revenue of $12.33B.

Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar

Related Articles

Disney Tops Q1 Results as Disney+ Shines

Macy's to close 125 department stores in next three years

Ford posts $1.7 billion quarterly loss, offers weak 2020 forecast